Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 4-5, 2010, Pages 277-282

  Masri, Selma ^a   Phung, Sheryl ^a   Wang, Xin ^a   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitor; Estrogen receptor; Microarray; Resistance

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AMPHIREGULIN; ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; LETROZOLE; MICRORNA; TAMOXIFEN; TESTOSTERONE; UO 126; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE; NITRILE; TRIAZOLE DERIVATIVE;

CELL STRAIN MCF 7; CONFERENCE PAPER; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION PROFILING; GENOME; HORMONE DEPENDENCE; HUMAN; LABORATORY; MICROARRAY ANALYSIS; SIGNAL TRANSDUCTION; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 77950357673     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.10.011     Document Type: Conference Paper

References (32)

1. C.J. Fabian, B.F. Kimler, Selective estrogen-receptor modulators for primary prevention of breast cancer, J. Clin. Oncol. 23 (8) (2005) 1644-1655.
2. R.W. Brueggemeier, J.C. Hackett, E.S. Diaz-Cruz, Aromatase inhibitors in the treatment of breast cancer, Endocr. Rev. 26 (3) (2005) 331-345.
3. Y. Hong, B. Yu, M. Sherman, Y.C. Yuan, D. Zhou, S. Chen, Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase, Mol. Endocrinol. 21 (2) (2007) 401-414.
4. A.S. Coates, A. Keshaviah, B. Thurlimann, H. Mouridsen, L. Mauriac, J.F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R.D. Gelber, M. Colleoni, et al., Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, J. Clin. Oncol. 25 (5) (2007) 486-492.
5. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S.E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N. Engl. J. Med. 350 (11) (2004) 1081-1092. (Pubitemid 38298988)
6. P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, M.J. Piccart, M. Castiglione, D. Tu, L.E. Shepherd, K.I. Pritchard, et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N. Engl. J. Med. 349 (19) (2003) 1793-1802.
7. A. Howell, J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J.F. Forbes, G. Hoctin-Boes, J. Houghton, G.Y. Locker, J.S. Tobias, Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet 365 (9453) (2005) 60-62.
8. S. Masri, S. Phung, X. Wang, X. Wu, Y.C. Yuan, L. Wagman, S. Chen, Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor, Cancer Res. 68 (12) (2008) 4910-4918.
9. S. Masri, K. Lui, S. Phung, J. Ye, D. Zhou, X. Wang, S. Chen, Characterization of the weak estrogen receptor alpha agonistic activity of exemestane, Breast Cancer Res. Treat. 116 (3) (2009) 461-470.
10. X. Wang, S. Masri, S. Phung, S. Chen, The role of amphiregulin in exemestaneresistant breast cancer cells: evidence of an autocrine loop, Cancer Res. 68 (7) (2008) 2259-2265.
11. X.Z. Sun, D. Zhou, S. Chen, Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells, J. Steroid Biochem. Mol. Biol. 63 (1-3) (1997) 29-36.
12. S. Chen, S. Masri, X. Wang, S. Phung, Y.C. Yuan, X. Wu,What do we know about the mechanisms of aromatase inhibitor resistance? J. Steroid Biochem. Mol. Biol. 102 (1-5) (2006) 232-240.
13. X. Wang, S. Chen, Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor, Cancer Res. 66 (21) (2006) 10281-10286.
14. A.J. Chien, P.E. Goss, Aromatase inhibitors and bone health in women with breast cancer, J. Clin. Oncol. 24 (33) (2006) 5305-5312.
15. P.E. Lonning, Bone safety of aromatase inhibitors versus tamoxifen, Int. J. Gynecol. Cancer 16 (Suppl. 2) (2006) 518-520.
16. E.A. Perez, Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer, Ann. Oncol. 18 (Suppl. 8) (2007), viii26-35.
17. R.E. Coleman, L.M. Banks, S.I. Girgis, L.S. Kilburn, E. Vrdoljak, J. Fox, S.J. Cawthorn, A. Patel, C.F. Snowdon, E. Hall, et al., Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study, Lancet Oncol. 8 (2) (2007) 119-127.
18. P.E. Goss, P. Hadji, M. Subar, P. Abreu, T. Thomsen, J. Banke-Bochita, Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women, Breast Cancer Res. 9 (4) (2007) R52.
19. J. Frasor, F. Stossi, J.M. Danes, B. Komm, C.R. Lyttle, B.S. Katzenellenbogen, Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells, Cancer Res. 64 (4) (2004) 1522-1533.
20. I. Martinez-Lacaci, M. Saceda, G.D. Plowman, G.R. Johnson, N. Normanno, D.S. Salomon, R.B. Dickson, Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines, Endocrinology 136 (9) (1995) 3983-3992.
21. C. Berasain, J. Castillo, M.J. Perugorria, J. Prieto, M.A. Avila, Amphiregulin: a new growth factor in hepatocarcinogenesis, Cancer Lett. 254 (1) (2007) 30-41.
22. M. Shoyab, G.D. Plowman, V.L. McDonald, J.G. Bradley, G.J. Todaro, Structure and function ofhumanamphiregulin: amember of the epidermal growth factor family, Science 243 (4894 Pt 1) (1989) 1074-1076.
23. G.J. Sabnis, L.F. Macedo, O. Goloubeva, A. Schayowitz, A.M. Brodie, Stopping treatment can reverse acquired resistance to letrozole, Cancer Res. 68 (12) (2008) 4518-4524.
24. K. Akakura, N. Bruchovsky, S.L. Goldenberg, P.S. Rennie, A.R. Buckley, L.D. Sullivan, Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen, Cancer 71 (9) (1993) 2782-2790.
25. J.T. Hsieh, H.C. Wu, M.E. Gleave, A.C. von Eschenbach, L.W. Chung, Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline, Cancer Res. 53 (12) (1993) 2852-2857.
26. J.J. Zhao, J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola, J.Q. Cheng, MicroRNA-221/222 negatively regulates estrogen receptor{alpha} and is associated with tamoxifen resistance in breast cancer, J. Biol. Chem. 283 (45) (2008) 31079-31086.
27. T.E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C.L. Shapiro, S. Jacob, S. Majumder, MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1, J. Biol. Chem. 283 (44) (2008) 29897-29903.
28. O. Kovalchuk, J. Filkowski, J. Meservy, Y. Ilnytskyy, V.P. Tryndyak, V.F. Chekhun, I.P. Pogribny, Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin, Mol. Cancer Ther. 7 (7) (2008) 2152-2159.
29. L. Fontana, M.E. Fiori, S. Albini, L. Cifaldi, S. Giovinazzi, M. Forloni, R. Boldrini, A. Donfrancesco, V. Federici, P. Giacomini, et al., Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM, PLoS ONE 3 (5) (2008) e2236.
30. L. Xia, D. Zhang, R. Du, Y. Pan, L. Zhao, S. Sun, L. Hong, J. Liu, D. Fan, miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells, Int. J. Cancer 123 (2) (2008) 372-379.
31. M. Garofalo, C. Quintavalle, G. Di Leva, C. Zanca, G. Romano, C. Taccioli, C.G. Liu, C.M. Croce, G. Condorelli, MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer, Oncogene 27 (27) (2008) 3845-3855.
32. H. Yang, W. Kong, L. He, J.J. Zhao, J.D. O'Donnell, J. Wang, R.M. Wenham, D. Coppola, P.A. Kruk, S.V. Nicosia, et al., MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN, Cancer Res. 68 (2) (2008) 425-433.